Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.33 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3345615 | 0.83 | ITGB2 (0.36) | — | |
| SCHEMBL161183 | 0.78 | ABCG2 (0.39) | AOC3ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL3404505 | 0.77 | ABCG2 (0.37) | AOC3ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL6904035 | 0.75 | ABCG2 (0.36) | AOC3ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL83574 | 0.75 | NQO2 (0.40) | AOC3ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL63619 | 0.71 | AOC3 (0.35) | AOC3ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL4060952 | 0.71 | TAAR1 (0.33) | AOC3ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL5907509 | 0.71 | NQO2 (0.37) | AOC3ABCG2ALDH1A1NQO2 | |
| SCHEMBL8612149 | 0.71 | CHRNB2 (0.35) | ABCG2TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL8925096 | 0.67 | ABCG2 (0.38) | ABCG2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683554-A | Pyrrolone fused ring derivatives, and methods for synthesizing and using the same | 重庆文理学院 | 2021-11-23 | — | — | CN | disclosed |
| US-7803945-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-09-28 | — | — | US | disclosed |
| US-7723523-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20090270378-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | NYCOMED GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| EP-1753512-B1 | TETRAHYDROPYRIDOTHIOPHENES | NYCOMED GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | ALTANA PHARMA AG (DE) | 2007-10-18 | — | — | US | disclosed |
| EP-1753512-A2 | TETRAHYDROPYRIDOTHIOPHENES | Altana Pharma AG (DE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118071-A2 | TETRAHYDROPYRIDOTHIOPHENES | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270378-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, BCL2, CCAR2 | AOC3 3914/4885ABCG2 1472/4885TXNRD1 235/4885 |
| US-20070244112-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, BAD | AOC3 3835/4885ABCG2 1544/4885TXNRD1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.